Harrow Health granted product-specific J-Code for Iheezo in ocular anesthesia

Harrow announced that the Centers for Medicare & Medicaid Services has issued a permanent, product-specific J-code for Iheezo 3% for ocular surface anesthesia. The Iheezo J-code will become effective April 1. Iheezo having its own permanent, product-specific J-code aims to enable a more efficient billing process for ophthalmologists, optometrists, and retina specialists. Iheezo is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, for ocular surface anesthesia. Iheezo was approved by the FDA on September 26, 2022. Iheezo is protected by an Orange Book-listed patent that is valid until 2038.